0000939767-23-000028.txt : 20230223 0000939767-23-000028.hdr.sgml : 20230223 20230223210812 ACCESSION NUMBER: 0000939767-23-000028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230221 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garber Alan M CENTRAL INDEX KEY: 0001312907 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 23662047 MAIL ADDRESS: STREET 1: 3355 MILTON COURT CITY: MOUNTAIN VIEW STATE: CA ZIP: 94040 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1851 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 1851 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 4 1 wf-form4_167720447178170.xml FORM 4 X0306 4 2023-02-21 0 0000939767 EXELIXIS, INC. EXEL 0001312907 Garber Alan M C/O EXELIXIS, INC. 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502 1 0 0 0 Common Stock 2023-02-21 4 M 0 40000 6.30 A 71417 D Common Stock 2023-02-21 4 S 0 40000 17.49 D 31417 D Option (right to buy) 6.3 2023-02-21 4 M 0 40000 0 D 2016-05-26 2023-05-25 Common Stock 40000.0 0 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 2, 2022. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 26, 2016. /s/ Nina Ayer, Attorney in Fact 2023-02-23